Telix at AdMeTech Summit on Precision Diagnosis and Treatment of Prostate Cancer
16 September 2021 – Clinical Spotlight | Telix to support and participate in AdMeTech 5th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer
Telix is delighted to announce our support for the AdMeTech 5th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer, to be held virtually from 23-25 September 2021.
We are also pleased to sponsor a session entitled: “PSMA PET/CT Imaging – Emerging Clinical Applications from a Urologic Perspective”, on Friday, 24 September 2021 at 8.28 am (EST), which will be presented by Dr. Neal Shore MD, FACS, Director & CPI at Carolina Urologic Research Center (CURC); Chief Surgical Officer and Head of Urology Research at Genesis Care USA; Founding Director at CUSP: Clinical Research Consortium, Myrtle Beach, South Carolina, with an opportunity for Q&A following the presentation.
Finally, we will be presenting an abstract entitled: “Safety of 68Ga -PSMA-11 prepared with the cold kit used in the Pivotal Lu-PSMA 617 Vision trial for selection of PSMA positive patients.”
To register for the AdMeTech 5th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer please click here.
To view the conference program please click here.
To view Telix’s accepted abstract please click here.
To return to the Telix homepage please click here.
Telix at ANZSNM Annual Scientific Meeting 2022
9 May 2022 – Corporate Spotlight | Telix supporting and participating in Australian and New Zealand Society of Nuclear Medicine...
First Patient Dosed in Phase II Renal Cancer Theranostics Study
Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 5 May 2022. Telix announces that a first patient has been dosed in...
Telix Further Strengthens European Distribution Network for Illuccix
Melbourne (Australia) and Liège (Belgium)– 22 April 2022. Telix announces agreements with Avanço and THP for the distribution of Telix’s...